Archive for the ‘Gene Therapy Research’ Category

The Angus Report, Nov. 19, 2012: Performance Insights
Tonya Amen of Angus Genetics Inc. explains AGI #39;s role in genetic evaluation and research, and its many contributions to the overall beef industry.From:apicreativemediaViews:1 0ratingsTime:01:52More inPets Animals

Originally posted here:
The Angus Report, Nov. 19, 2012: Performance Insights - Video

How To Grow Taller - My Real Life Experience Advice.mp4
Hey, guys, what #39;s up. i am creating this video to direct all of you guys who are obsessed of their height and always wishing for a miracle that will increase your height in minutes, now let me tell you even if you buy this eBook ( like rest of the countless peoples ) get all the researched steps in your hand, steps which is proven after years of research by the scientist out there. But If you are not going to correctly follow the steps in the book with needed hard work, please leave this video right now, because if you are not going to put your dedicated effort with this steps by steps course you won #39;t gain a inch and that #39;s for sure ! ( if you are in a great hurry and don #39;t want to wait, go for a surgery which will cost you thousand of dollars and a lot of pain 🙁 i don #39;t know nothing about it so, google it) Do you know ? Every passing day you loose the chances of effective height growth so i suggest you to start as quickly as possible and start doing those stretch exercises shown in the course and eat what #39;s written in that book. One of the secret fact from the ebook: every morning you height is increased a few inches that comes backs to your actual height after a few hours, why ? its because when your body is in the position of rest the spine stretches a few inches 🙂 Please don #39;t put your money in this eBook if you are above 28, it may work for some people, depending on their physic and genetics. but its just a fair advice from my side. This is the ebook course i ...From:BangonandoffViews:1 0ratingsTime:01:23More inHowto Style

Read the original here:
How To Grow Taller - My Real Life Experience

How to Pronounce Haldane
Learn how to say Haldane correctly with EmmaSaying #39;s "how do you pronounce" free tutorials. Definition of Haldane, JBS (oxford dictionary): (1892--1964), Scottish mathematical biologist; full name John Burdon Sanderson Haldane. As well as contributing to the development of population genetics, Haldane became well known as a popularizer of science and as an outspoken Marxist. http://www.emmasaying.comFrom:Emma SayingViews:0 0ratingsTime:00:11More inHowto Style

Read the original here:
How to Pronounce Haldane - Video

Breaking Down Pulmonary Embolism
When tennis star Serena Williams was treated for a pulmonary embolism, many people didn #39;t know what it was. A pulmonary embolism results when a blood clot travels from another part of the body, usually the legs, and lodges in the lungs. "The blood clot itself gets bigger and bigger until it reaches its threshold and it breaks off. Then it starts traveling through your body and it travels to the point of least resistance, smallest blood vessel, which happens to be the lungs," says Dr. Javaad Khan, a pulmonologist and critical care physician with Lee Memorial Health System. The condition not as rare as you might think Some 6 million people develop a blood clot every year, about 600-thousand of them end up with a pulmonary embolism. It can be fatal, but it is also very treatable. "If you #39;ve developed one blood clot, the treatment is usually three to six months with the blood thinners. If you have a blood disorder, which predisposes you we keep you on it for life," says Dr. Khan. A large clot can lead to heart failure, and may require an immediate delivery of clot busting drugs. "If you have heart failure, radiologists can either put a catheter directly into that vessel itself and give a clot buster from a thrombolytic type of medicine and it dissolves the clot almost instantaneously. ER physicians can also nurse that blood clotting medicine but they do it through an IV in your arm," says Dr. Khan. Pulmonary embolisms are linked to deep vein thrombosis, along with ...From:LeeMemorialMarketingViews:0 0ratingsTime:01:41More inScience Technology

Continued here:
Breaking Down Pulmonary Embolism - Video

NEWARK, N.J. On April 14, 2011, James Fan stood on a parking-garage landing at Newark Liberty International Airport, a cheer-you-up letter from his young son in his pants pocket, the prospect of a four-story leap facing him.

Fan, 39, had been charged a day earlier with insider trading based on his knowledge of Seattle Genetics, a health-care company where he was manager of clinical programming. Also charged: his younger brother, Zishen, who was scheduled to take the oath of U.S. citizenship a month later.

The total take, a judge later determined, was about $200,000. James Fan was trying to help his brother, who had found himself deep under water after the California real-estate market collapsed in 2008, prosecutors said later.

The Fan case is such a cautionary tale, said Jenny Durkan, the U.S. attorney in Seattle. Both brothers were promising.

The markets are awash in insider trading, and the health-care industry has been particularly hard-hit. Health-care businesses offer illegal traders more opportunities to profit than the finance and technology sectors that have traditionally been prime victims of insiders who leaked confidential data about earnings or deals.

Health companies can live or die on the results of drug trials, which stretch for years before regulators make decisions that can trigger hundreds of millions of dollars in profits or losses. And the industry has undergone significant consolidation, leading to several multibillion-dollar mergers.

The lineup of accused health-industry insider traders illustrates how widespread the illegal practice has become: chief executive officers, hedge-fund traders, bankers, lawyers, doctors, accountants, a retired Delta Air Lines pilot, a film producer and a member of Major League Baseballs Hall of Fame have been charged or sued by regulators.

Health care is particularly attractive to criminals because so much turns on the government regulatory approval, said Rod Rosenstein, the U.S. attorney for Maryland, whose office helped prosecute the Food and Drug Administration (FDA) case. If you have a pending application for a new drug, the difference between yes and no on approvals can be tens or hundreds of millions of dollars.

The Fans are among at least 75 people sued by the Securities and Exchange Commission (SEC) or charged since 2008 with passing or receiving insider-trading tips involving pharmaceutical, biotechnology or other health care stocks.

One health-care inside trader turned informant told the FBI he was once on a golf course with three doctors whose beepers all went off at the same moment with the same inside tip.

Go here to read the rest:
Lure of riches leads to suicide in Seattle Genetics stock case

The Hidden Source Episode 29 -HIDDEN HACKER?-
Myself ThatOneRebel playing some The Hidden Source! Nobody can see The Hidden only trained eyes can see him well! WATCH AS I MURDER EVERYONE AS THE HIDDEN MAHAAAHAHAHA The objective of The Hidden Source is that the humans aka IRIS must eliminate The Hidden to win vice versa for the Hidden but as the title says he is invisible and only is equipped with a knife capable of a one hit kill depending on server and only three grenades. The hidden has many abilities like taunting, super strength to ram objects into IRIS soldiers or be able to leap super high and hang on buildings. Lastly The Hidden can heal himself by eating bodies but only if they are stabbed to death not PIGSTICKED! (which is the one hit kill move) The IRIS are equipped with four weapons ranging from shotgun to rifle to SMG and a few options of equipment like senors to laser optics on your gun. Game is The Hidden Source which requires Half life 2 engine meaning you have to have Half Life 2 purchased already or another source game to run with STORYLINE In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid ...From:ThatOneRebel55Views:1 0ratingsTime:11:31More inGaming

Continue reading here:
The Hidden Source Episode 29 -HIDDEN HACKER?- - Video

#39;Suicide Gene #39; Being Introduced to Moths
#39;Suicide Gene #39; Being Introduced to Moths - YouTube #9658; 3:11 #9658; 3:11 http://www.youtube.com/watch?v=5Fz1KuWaNP8 NOVO13 horas atrás - 3 min - Vídeo enviado por TheYoungTurks "Millions of GM insects developed by British scientists could be released into food crop fields without proper ... #39;Suicide Gene #39; Being Introduced to Moths - YouTube #9658; 3:11 #9658; 3:11 http://www.youtube.com/watch?v=5Fz1KuWaNP8... NOVO13 horas atrás - 3 min - Vídeo enviado por TheYoungTurks "Millions of GM insects developed by British scientists could be released into food crop fields without proper ... Mais vídeos para #39;Suicide Gene #39; Being Introduced to Moths » Action Jackson #39;s thoughts: #39;Suicide Gene #39; Being Introduced to Moths actionjackson1989.blogspot.com/.../suicide-gene... - Traduzir esta página 3 hours ago -- Cenk Uygur and Ana Kasparian discuss genetic modification to food and animals. Is engineering a moth with a #39;suicide gene #39; going too far, and ... How do you think a moth could commit suicide? - Yahoo!7 Answers au.answers.yahoo.com/question/index?... - Austrália - Traduzir esta página 1 resposta - 22 horas atrás I was reading an article that said a company was introducing a "suicide gene" into moths that plague food crops in the US O_o It didn #39;t say how ... THE STORY OF THE SUICIDE GENE - HiddenMysteries Health ... http://www.hiddenmysteries.org/.../suicidegene.html - Traduzir esta página The suicide gene is hard to trigger, but when some unknown factor does it, there is no turning back. ... Without the gene being ...From:foxnews630Views:0 0ratingsTime:03:11More inEntertainment

View original post here:
'Suicide Gene' Being Introduced to Moths - Video

GAINESVILLE, Fla.--(BUSINESS WIRE)--

Applied Genetic Technologies Corporation, (AGTC), a privately-held, clinical stage biotechnology company developing gene therapy products to treat rare retinal diseases, announced today that it has secured $37.5 million in a Series B round of financing.

Alta Partners and S.R. One, Limited led the financing, with new investor Osage University Partners joining existing investors InterWest, Intersouth Partners and MedImmune Ventures in the round. The funding will allow AGTC to continue development of its Phase 2 program in Alpha-1 Antitrypsin Deficiency (Alpha-1) and initiate full development of potential treatments for two orphan ophthalmology indications, Achromatopsia (ACHM) and X-Linked Rentinoschisis (XLRS).

"We are strong believers in the business model of developing treatments for genetic disorders," said Ed Hurwitz, General Partner of Alta Partners. "Based on encouraging clinical results from AGTC and others, we concluded that a large set of genetically defined diseases could be cured using AGTCs proprietary vectors and manufacturing technologies. The Series B financing is designed to move several of AGTCs programs through proof of concept as well as to allow the company to leverage its manufacturing and development infrastructure with partners to accelerate a broad portfolio of curative products.

ACHM is an inherited genetic condition that presents at birth with impaired visual acuity. Most patients are legally blind, lacking color discrimination and experiencing extreme light sensitivity, resulting in daytime blindness. ACHM is caused by mutations in a group of genes which make the cone cells concentrated in the central retina non-functional. There is no treatment for Achromatopsia, although deep red tinted spectacles or contact lenses can reduce symptoms of light sensitivity. Approximately 22,000 patients in the US and Europe suffer from this disease.

AGTCs potential treatment uses an adeno-associated virus (AAV), a safe, man-made virus that delivers healthy copies of the ACHM gene to the cells of the retina, replacing the defective copies of the gene. A single treatment is expected to halt the disease for several years, perhaps a lifetime. The AAV delivery system is successfully being used in clinical trials of Leber congenital amaurosis gene therapy that have restored vision in more than 50 adults and children who were virtually blind. Previous research has shown promising signs of efficacy in dog models of ACHM.

XLRS, an inherited genetic condition, is a leading cause of juvenile macular degeneration in males. It is caused by mutations in the RS1 gene, which results in the layers of the central retina splitting. Patients typically begin to experience progressive vision loss between the ages of 5 and 10. Other early symptoms include the inability to focus both eyes and roving, involuntary eye movements. No treatment for XLRS is currently available. Approximately 35,000 patients in the US and Europe suffer from this disease. Previous research has shown promising signs of efficacy in rodent models of XLRS.

About AGTC

AGTC is focused on the research and development of novel therapeutics for patients with unmet medical needs utilizing AGTCs proprietary, non-pathogenic adeno-associated virus (AAV) delivery system. AGTC has demonstrated that this system can be used to deliver a normal form of a gene in both animals and humans thus allowing their own body to produce sustained therapeutic levels of important biologics. The Companys most advanced programs in development are treatments for Alpha-1 antitrypsin deficiency (Alpha-1) a disease causing a progressive loss of lung function, and Lebers Congenital Amaurosis, an inherited condition causing early blindness. Both utilize AGTCs proprietary AAV system and production methods.

About Alta Partners

Read more from the original source:
AGTC Secures $37.5M Series B Funding

SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease, as is employed in Cardium's Generx gene therapy candidate currently in late-stage clinical studies. Following a decision by the European Patent Office, Cardium's patent portfolio now includes allowed and issued patents covering its gene therapy approach both in Europe and in the United States, with competing patent applications licensed and pursued by Boston Scientific having been successfully overcome in both Europe and the U.S.

(Logo:http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The competing patent applications licensed by Boston Scientific Corporation had been filed by Dr. Jeffrey Leiden et al., currently President & CEO of Vertex Pharmaceuticals, and had been the subject of opposition proceedings in Europe and interference proceedings in the United States, both of which were ultimately resolved in favor of Cardium. Following resolution of the opposition proceedings and further examination of Cardium's case, the European Patent Office has now approved Cardium's patent application for grant in Europe. Three corresponding U.S. Patents that had been challenged by Boston Scientific Corporation (in decisions that were appealed to the United States Court of Appeals for the Federal Circuit), have been affirmed in Cardium's favor.

Cardium has additional patents and patent applications directed to its methods of cardiovascular gene therapy in the U.S., Europe, Russia and elsewhere, and the company recently filed new patent applications directed to certain improved techniques for the treatment of heart disease that are currently the subject of a Phase 3 registration trial based in Moscow, which is designed to generate additional safety and effectiveness data for the Russian Federation and other jurisdictions. Generx (alferminogene tadenovec) is intended to stimulate the growth of collateral blood vessels to effectively bypass coronary artery atherosclerotic blockages without the need for surgical procedures or angioplasty and stents; and its safety and effectiveness have been the subject of clinical studies involving more than 650 patients in the U.S., Europe and elsewhere. Generx has been assigned the trade name Cardionovo for planned commercialization in the Russian Federation. Cardium believes that its Generx clinical database represents the largest and most complete gene therapy dossier and is directed to a major medical indication that is a leading cause of death throughout the developed world.

"The resolution of these important reviews of our gene therapy patents, and the consistent decisions in our favor including rulings by the U.S. courts of appeal, underscore the value of our patent portfolio, which we believe reflects a breakthrough approach to the treatment of coronary heart disease," said Dr.TylerM.Dylan-Hyde, Chief Business Officer and General Counsel of Cardium Therapeutics.

Recently-published findings demonstrate that Cardium's innovative technique employing transient cardiac ischemia can be used to dramatically enhance gene delivery and transfection efficiency after one-time intracoronary administration of adenovector in mammalian hearts. Two consecutive but brief periods of coronary artery occlusion combined with co-administration of nitroglycerin increased both adenovector presence (measured by PCR) and transgene expression (assessed by luciferase activity) by over two orders of magnitude (>100 fold) in the heart, as compared to prior intracoronary artery delivery methods.

The research results published in Human Gene Therapy Methods extend those findings and demonstrate that Cardium's new technique for adenovector gene delivery in the heart can be used to dramatically boost adenovector delivery. By enhancing uptake even in patients with less severe forms of disease and ischemia, it would be expected to reduce response variability and allow for the potential treatment of patients with a broader range of associated coronary artery disease. The new treatment protocols for Cardium's recently-initiated ASPIRE clinical study have been developed to use this improved knowledge about induced transient ischemia techniques to enhance the non-surgical, catheter-based delivery of Generx to the heart.

Cardium has also been actively advancing its Generx product candidate's engineering and process technology in preparation for commercialization. The Company successfully transferred a refined, improved and fully-validated manufacturing process to SAFC, the custom manufacturing and services business unit of Sigma-Aldrich Corporation (SIAL), a top global specialty chemicals and biologics supplier, located in Carlsbad, California. As a result of the rigorous technical transfer process, important process improvements were achieved enabling much higher manufacturing process yields. Generx's long-term product stability has been established at a minimum of six years making it possible to manufacture product in large, cost effective batch sizes. The dose preparation process for Generx has been simplified through the integration of a fully-validated, closed-system drug transfer process incorporating the use of PhaSeal System passive safety technology to streamline and simplify the cath-lab preparation and eliminating the need to prepare Generx in a sterile, biological safety hood. The Company has also developed a new and unique, fully-validated bio-activity release assay to measure and evaluate the pro-angiogenic potency of each newly manufactured batch of Generx.

The European Commission's recent approval of uniQure's Glybera (alipogene tiparvovec) the first gene therapy approval by a major health regulatory authority is considered to represent a significant milestone and validation for the gene therapy industry.

About Generx and the ASPIRE Study

See original here:
Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart Disease

Marie McCullough, Inquirer Staff Writer Posted: Monday, November 19, 2012, 3:01 AM

The first gene therapy in the Western Hemisphere will soon be available in Europe.

The approval of Glybera by European regulators happened with little fanfare in September, in contrast to the hype that surrounded gene therapy 20 years ago.

But it is truly a breakthrough for the field, for people with the ultrarare disease it treats - and for University of Pennsylvania scientist James M. Wilson, a creator of the modified virus that delivers the therapeutic gene.

Wilson began to focus on finding safe, efficient gene-delivery viruses, or vectors, after a study he led caused the 1999 death of Arizona teenager Jesse Gelsinger - the world's first gene-therapy victim.

The vector in that study triggered a fatal immune system overreaction. The fallout set off years of government investigations and efforts to improve human-subject protections.

Entertainment Today

Latest Entertainment Stories

Stay Connected

Get the latest news and events delivered to your email. Sign up now!

Excerpt from:
Gene breakthrough after sad setback

Placenta Extract
Buy from Amazon US redirect.viglink.com?key=f341fd9454fc162be8b38d504acbd4e1 out=http%3A%2F%2Fwww%2Eamazon%2Ecom%2Fexec%2Fobidos%2FASIN%2FB007250F6K%2Fhealth%5Fhope%2D20 Customer Reviews "My wife has used these Placenta Softgels for 3 months. Not only did she notice a reduction of wrinkles and a new firmness in her skin, she also noticed that she didn #39;t suffer any colds last winter. These softgels are a great booster for the immune system and they revitalize the skin. My wife plans on using them for 3 months every year instead of doing cell therapy injections that cost a lot and require traveling." "I received a box of these Placenta capsules as a gift last december. I usually go through 4 to 5 colds every winter, but not last winter. Not one cold bothered me. I also noticed an improvement of my facial skin. It appears smoother, firmer and revitalized. I will order more of these every autumn and use them to boost my immune system and give my skin a mini spa." Product Description Placenta Extract MFIII of Switzerland PE Softgels Advanced Formula 2009 are fully researched and developed in Switzerland and Germany. The method employed in unique softgel capsules produces cells which remain biologically active [a proven technique for gently conserving biological substances] without damaging the effectiveness of the valuable, big, bio-active matter. The exact dosage of the cell preparations can be accurately measured and the sterility controlled. Cell Therapy is a well known ...From:leonor christyViews:0 0ratingsTime:00:56More inHowto Style

Originally posted here:
Placenta Extract - Video

ZÉLL-V Sheep Placenta Anti Aging Satisfied Customer - Winnie
http://www.zell-v.com We specialise in cell therapy products for anti aging. we are supported by an international medical board of practitioners, biologist and wellness professionals.From:zellvsheepplacentaViews:8 0ratingsTime:01:33More inHowto Style

Visit link:
ZÉLL-V Sheep Placenta Anti Aging Satisfied Customer - Winnie - Video

Mrs. Linda Flournoy
describes ger experience with Stem Cell Therapy PRPFrom:FLRegenerativeMedViews:2 0ratingsTime:02:27More inEducation

See the article here:
Mrs. Linda Flournoy - Video

Stem Cell Therapy | Stem Cell Malaysia
stemcellmalaysia.com Stem cell therapy is a form of cell therapy that makes use of stem cells harvested from placenta for disease treatment. Stem cell therapy is also used for beauty, anti-aging and health rejuvenation purposes. The efficacy of stem cell therapy has been in practice for decades. Many rich and wealthy individuals and celebrities pay hefty price for stem cell therapy just to maintain youthfulness and vitality. For many severely ill-stricken people who have exhausted all means of conventional therapy look toward stem cell therapy for saving their condition and life. stemcellmalaysia.comFrom:stemcells2012Views:224 2ratingsTime:07:23More inHowto Style

View post:
Stem Cell Therapy | Stem Cell Malaysia - Video

Published: Thursday, November 15, 2012, 12:01 a.m.

The problem gene is not common -- less than 1 percent of people are thought to have it -- but it roughly triples the chances of developing Alzheimer's compared to people with the normal version of the gene. It also seems to harm memory and thinking in older people without dementia.

The main reason scientists are excited by the discovery is what this gene does, and how that might reveal what causes Alzheimer's and ways to prevent it. The gene helps the immune system control inflammation in the brain and clear junk such as the sticky deposits that are the hallmark of the disease. Mutations in the gene may impair these tasks, so treatments to restore the gene's function and quell inflammation may help.

"It points us to potential therapeutics in a more precise way than we've seen in the past," said Dr. William Thies, chief medical and scientific officer of the Alzheimer's Association, which had no role in the research. Years down the road, this discovery will likely be seen as very important, he predicted.

It is described in a study by an international group published online Wednesday by the New England Journal of Medicine.

About 35 million people worldwide have dementia, and Alzheimer's is the most common type. In the U.S., about 5 million have Alzheimer's. Medicines such as Aricept and Namenda just temporarily ease symptoms. There is no known cure.

Until now, only one gene -- ApoE -- has been found to have a big impact on Alzheimer's risk. About 17 percent of the population has at least one copy of the problem version of this gene but nearly half of all people with Alzheimer's do. Other genes that have been tied to the disease raise risk only a little, or cause the less common type of Alzheimer's that develops earlier in life, before age 60.

The new gene, TREM2, already has been tied to a couple other forms of dementia. Researchers led by deCODE Genetics Inc. of Iceland honed in on a version of it they identified through mapping the entire genetic code of more than 2,200 Icelanders.

Further tests on 3,550 Alzheimer's patients and more than 110,000 people without dementia in several countries, including the United States, found that the gene variant was more common in Alzheimer's patients.

"It's a very strong effect," raising the risk of Alzheimer's by three to four times -- about the same amount as the problem version of the ApoE gene does, said Dr. Allan Levey, director of an Alzheimer's program at Emory University, one of the academic centers participating in the research.

Original post:
Scientists identify new Alzheimer's gene

London, November 17 (ANI): Scientists at Manchester University have revealed that they have discovered 14 genes that lead to rheumatoid arthritis, making a major breakthrough in their bid to find a cure for the condition.

Lifestyle and environmental factors, such as smoking, diet, pregnancy and infection may cause the complicated disease, but a person's genetic make-up also influences their susceptibility.

Manchester University scientists believe they now know most of the disease-causing genes with the latest research identifying ones specific to the female X-chromosome.

The discovery, published in the journal Nature Genetics, could explain why three times more women than men develop the illness and scientists can use these findings to try to stop the disease from developing.

"This work will have a great impact on the treatment of arthritis. We have already found three genes that are targets for drugs, leaving 43 genes with the potential for drug development, helping the third of patients who fail to respond well to current medications," the Daily Express quoted study author Dr Stephen Eyre as saying.

"The genetic findings can help divide patients into smaller groups with more similar types of rheumatoid arthritis and assist in the allocation of therapies," he noted.

The team studied 27,000 DNA samples to identify the new genes and move closer to improving the lives of rheumatoid arthritis sufferers.

Professor Alan Silman, medical director of Arthritis Research UK, added: "We hope that this research will lead to a greater understanding of the disease and allow us to develop targeted drug treatments for the people currently living with rheumatoid arthritis. (ANI)

Read more:
Gene discovery shows promise in arthritis cure

Scientists have discovered another gene mutation that may indicate if a person is more likely to get Alzheimer's, a remarkable breakthrough in a field that hasn't seen major progress in a decade.

Two independent studies published in the New England Journal of Medicine on Nov. 14 revealed that people who had a certain mutation on their TREM2 gene were shown to be three to five times more likely to get Alzheimer's than those without the mutation. The rate is comparable to the number of people who get late-onset Alzheimer's who have an ApoE4 gene mutation, which is about 40 percent.

27 Photos

8 Photos

When a person has a working TREM2 gene, their white blood cells get rid of a plaque-forming protein known as beta amyloid that builds up on cells connected to inflammatory response called microglia, the New York Times reported. People who have the genetic mutation variant R47H on the gene aren't able to clean up their cells. Scientists believe that beta amyloid plaque on the brain is one of the markers of the disease.

"This discovery provides an increasingly firm link between brain inflammation and increased risk for Alzheimer's," Dr. Peter St. George-Hyslop, director of University of Toronto's Tanz Centre for Research in Neurodegenerative Diseases, said in a press release. "This is an important step towards unraveling the hidden causes of this disease, so that we can develop treatments and interventions to end one of the 21st century's most significant health challenges."

Alzheimer's disease is the most common form of dementia, affecting 5.4 million Americans according to the Alzheimer's Association. About one in eight elderly people living in the U.S. have the disease. It is the sixth-leading cause of death and the only one in the top 10 that cannot be prevented, cured or slowed. The disease, which usually occurs later in life in people 65 and older, starts with mild memory loss and progresses to the inability to carry a conversation or to recognize one's environment.

Recent studies have shown that Alzheimer's signs may be seen decades before diagnosis in people who have PSEN1 gene mutation, which has been linked to the early-onset form of the disease.

Clinical trials will test new drugs solanezumab from Eli Lilly and gantenerumab from Roche on their effectiveness of preventing the disease. Previously in July, solanezumab and bapineuzumab made by Pfizer were shown to be ineffective in treating people with late-stage and mild-to-moderate forms of Alzheimer's respectively. Solanezumab did show promise in treating mild forms, however.

Scientists came to the conclusion about the TREM2 mutation after two studies showed similar results. One study, which was led by researchers at the University College London among other universities, studied the DNA of 1,092 people with Alzheimer's disease and 1,107 people without the disease. The R47H mutation was found in approximately 1.9 percent of the group with the disease and only 0.37 percent of control group. They then tested a larger pool of about 6,700 Alzheimer's patients and 16,200 people without the disease to confirm their results.

See the original post here:
Gene mutation identified as new risk factor for Alzheimer's

Scientists have identified a new gene variant that seems to strongly raise the risk for Alzheimers disease, giving a fresh target for research into treatments for the mind-robbing disorder.

The problem gene is not common less than 1 per cent of people are thought to have it but it roughly triples the chances of developing Alzheimers compared to people with the normal version of the gene. It also seems to harm memory and thinking in older people without dementia.

The main reason scientists are excited by the discovery is what this gene does, and how that might reveal what causes Alzheimers and ways to prevent it. The gene helps the immune system control inflammation in the brain and clear junk such as the sticky deposits that are the hallmark of the disease. Mutations in the gene may impair these tasks, so treatments to restore the genes function and quell inflammation may help.

It points us to potential therapeutics in a more precise way than weve seen in the past, said Dr. William Thies, chief medical and scientific officer of the Alzheimers Association, which had no role in the research. Years down the road, this discovery will likely be seen as very important, he predicted.

It is described in a study by an international group published online Wednesday by the New England Journal of Medicine.

About 35 million people worldwide have dementia, and Alzheimers is the most common type. In Canada, about 500,000 people have Alzheimers or related dementia, according to the Alzheimer Society of Canada. Current medicines just temporarily ease symptoms. There is no known cure.

Until now, only one gene ApoE has been found to have a big impact on Alzheimers risk. About 17 per cent of the population has at least one copy of the problem version of this gene but nearly half of all people with Alzheimers do. Other genes that have been tied to the disease raise risk only a little, or cause the less common type of Alzheimers that develops earlier in life, before age 60.

The new gene, TREM2, already has been tied to a couple other forms of dementia. Researchers led by deCODE Genetics Inc. of Iceland honed in on a version of it they identified through mapping the entire genetic code of more than 2,200 Icelanders.

Further tests on 3,550 Alzheimers patients and more than 110,000 people without dementia in several countries found that the gene variant was more common in Alzheimers patients.

Its a very strong effect, raising the risk of Alzheimers by three to four times about the same amount as the problem version of the ApoE gene does, said Dr. Allan Levey, director of an Alzheimers program at Emory University in Atlanta, one of the academic centres participating in the research.

Excerpt from:
Gene may triple Alzheimer’s risk

By Steven Reinberg HealthDay Reporter

WEDNESDAY, Nov. 14 (HealthDay News) -- A rare mutation in a gene called TREM2 appears to nearly triple the risk for Alzheimer's disease in adults, a new study finds.

This gene is involved in immune and inflammatory responses, and may be yet another piece of the mystery of the causes of Alzheimer's disease and a target for treatment, the researchers added.

"We found a mutation that confers a large risk for Alzheimer's disease," said lead researcher Dr. Kari Stefansson, the CEO of deCODE Genetics based in Reykjavik, Iceland.

Although only 1.2 percent of the population has the TREM2 mutation, when comparing adults aged 85 and older with and without it, those who do have it are almost seven times more likely to have Alzheimer's disease, he said.

Of course, having this mutation doesn't mean that one is destined to develop Alzheimer's disease. Alzheimer's is a complex disease and a person probably needs to have several risk factors that combine to produce the condition, Stefansson said.

"This has implications for treatment," he said. The mutation might be a target for new drugs that blunt the mutation's action, he said.

The report was published in the Nov. 14 online edition of the New England Journal of Medicine.

An Alzheimer's expert praised the new study.

"This shows the value of basic research," said William Thies, chief medical and scientific officer at the Alzheimer's Association. "This kind of science is very important, and can accelerate our finding better therapies for Alzheimer's disease."

Continued here:
Scientists ID Gene Mutation That May Triple Alzheimer's Risk

Public release date: 16-Nov-2012 [ | E-mail | Share ]

Contact: Bonnie Prescott bprescot@bidmc.harvard.edu 617-667-7306 Beth Israel Deaconess Medical Center

BOSTON Many of the body's processes follow a natural daily rhythm or so-called circadian clock. There are certain times of the day when a person is most alert, when blood pressure is highest, and when the heart is most efficient. Several rare gene mutations have been found that can adjust this clock in humans, responsible for entire families in which people wake up at 3 a.m. or 4 a.m. and cannot stay up much after 8 at night. Now new research has, for the first time, identified a common gene variant that affects virtually the entire population, and which is responsible for up to an hour a day of your tendency to be an early riser or night owl.

Furthermore, this new discovery not only demonstrates this common polymorphism influences the rhythms of people's day-to-day lives -- it also finds this genetic variant helps determine the time of day a person is most likely to die.

The surprising findings, which appear in the November 2012 issue of the Annals of Neurology, could help with scheduling shift work and planning medical treatments, as well as in monitoring the conditions of vulnerable patients.

"The internal 'biological clock' regulates many aspects of human biology and behavior, such as preferred sleep times, times of peak cognitive performance, and the timing of many physiological processes. It also influences the timing of acute medical events like stroke and heart attack," says first author Andrew Lim, MD, who conducted the work as a postdoctoral fellow in the Department of Neurology at Beth Israel Deaconess Medical Center (BIDMC).

"Previous work in twins and families had suggested that the lateness or earliness of one's clock may be inherited and animal experiments had suggested that the lateness or earliness of the biological clock may be influenced by specific genes," adds Lim, who is currently an Assistant Professor in the Division of Neurology at the University of Toronto.

The work originated several years ago while Lim was working in the laboratory of BIDMC Chief of Neurology Clifford Saper, MD, PhD. Lim and the other lab members were studying why older people have trouble sleeping and had joined a research project based at Rush University in Chicago involving 1,200 people who signed on as healthy 65-year-olds and would receive annual neurological and psychiatric examinations.

The cohort's original intent was to determine if there were identifiable precursors to the development of Parkinson's disease or Alzheimer's disease. As part of the research the subjects were undergoing various sleep-wake analyses using a wristband called an actigraph, which provides a reliable record of an individual's pattern of activity. Additionally, in order to provide the scientists with information on sleep-wake patterns within a year of death, the participants had agreed to donate their brains after they died.

But the investigation took a new turn when Lim learned that the same group of subjects had also had their DNA genotyped. Teaming up with investigators from Brigham and Women's Hospital (BWH), Lim and his colleagues compared the wake-sleep behavior of these individuals with their genotypes. These findings were later verified in a group of young volunteers.

See the original post:
Gene distinguishes early birds from night owls and helps predict time of death

Food Water Watch Genetic Engineering (GE) Labeling Campaign
DAVENPORT, IOWA | November 14, 2012 - Leann Felder coordinator for Food Water Watch, Russ Neff for Sierra Club, Curtis Rexroth, MA, DC, CCN of the Rexroth Clinic in Moline, IL address a group of concerned citizens regarding a campaign branded, "Let Me Decide: Iowans Campaign to Make the Labeling of Genetically Engineered Foods the Law". The meeting was hosted at Greatest Grains in Davenport, Iowa.From:QCATodayViews:7 0ratingsTime:39:23More inNews Politics

See the article here:
Food

The Day of the Triffids Full Movie HD
Watch full movie : tinyurl.com The Day of the Triffids Full Movie HD, The Day of the Triffids Part 1 Movie, The Day of the Triffids Movie Part 1, The Day of the Triffids Part 1 The Movie, The Day of the Triffids Part 2 Full Movie, The Day of the Triffids Movie Full Movie, The Day of the Triffids (2013) Movie Part 1 English Full, The Day of the Triffids Movie HD trailer. An epic tale of mankind #39;s self-annihilation in the wake of a cosmic event leading to global blindness. His legacy in genetic engineering changed the hierarchy of nature, toppling mankind #39;s place atop the world #39;s food chain.From:doriana dimcevViews:2 0ratingsTime:04:21More inFilm Animation

Excerpt from:
The Day of the Triffids Full Movie HD - Video

Genetic Engineering Persuasive Informercial
From:Chloe DurkinViews:7 1ratingsTime:02:49More inNews Politics

Read more:
Genetic Engineering Persuasive Informercial - Video

Genetic Engineering Controversy
A presentation on genetic modification for our freshmen seminar at Penn State University. We discuss the issues and facts surrounding the controversy about genetically modified foods, animals, and plants.From:Benjamin FowlerViews:8 0ratingsTime:33:08More inScience Technology

Excerpt from:
Genetic Engineering Controversy - Video

The End Of The World - John Leslie
ll4.me The End Of The World - John Leslie Nuclear war, holes in the ozone layer, disease, genetic engineering, asteroids and supernovas - any of these may bring human history to an end. But are we in imminent danger of extinction? John Leslie assesses the risks facing the human race and concludes: yes, we probably are. Leslie pays particular attention to the #39;doomsday argument #39;. This argument, arising from the undeniable fact that we are a very young species, substantially increases the likelihood of our extinction.Author: Leslie, John Publisher: Routledge Illustration: N Language: ENG Title: The End of the World Pages: 00000 (Encrypted PDF) On Sale: 1998-03-12 SKU-13/ISBN: 9780415140430 Category: Education : Teaching Methods Materials - Arts Humanities Nuclear war, holes in the ozone layer, disease, genetic engineering, asteroids and supernovas - any of these may bring human history to an end. But are we in imminent danger of extinction? John Leslie john leslie, education, teaching methods, materials, arts, humanitiesFrom:heathertrull9854Views:0 0ratingsTime:00:10More inPeople Blogs

Follow this link:
The End Of The World - John Leslie - Video